Molecular Mechanisms Underlying Neuroprotective Effects of Albumin After Ischemic Stroke

Parkkinen, Jaakko; Ojala, Pauli J.; Niiranen, Jenni; Jolkkonen, Jukka

doi:10.1161/01.str.0000254506.06583.2d

Cited by 9 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Albumin is recognized as an important antioxidant in plasma which might play a beneficial role during the delayed phase of neuronal death [12]. It is also speculated that albumin might exert neuroprotection by binding to lysophosphatidylcholine (lyso PC) [13]. Free lyso PC upregulates leukocyte adhesion molecules and thereby induces pro-inflammatory action on vascular endothelium.…”

Section: Discussionmentioning

confidence: 99%

Serum Albumin in Ischemic Stroke Patients: The Higher the Better

Idicula

Waje‐Andreassen²,

Brøgger³

et al. 2009

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: Animal studies show a neuroprotective effect of serum albumin in ischemic stroke. The neuroprotective effect of albumin in ischemic stroke in humans is not well studied. This study was aimed to determine the association of serum albumin with outcome and mortality after ischemic stroke. Methods: In a prospective study, we included 444 patients with ischemic stroke. Serum albumin was measured at the time of admission. Stroke severity was measured at the time of admission with the National Institutes of Health Stroke Scale (NIHSS). Functional outcome was measured with the modified Rankin scale (mRS) on day 7. Multiple logistic regression analysis was used to assess the independent association between variables and outcome. Survival was analyzed by Cox regression analysis after adjusting for age, sex and NIHSS score on admission. Results: The mean age (SD) of the patients was 70.4 (14.4) years. The median NIHSS score (interquartile range) on admission was 4 (1–8) and the median mRS score (interquartile range) on day 7 was 2 (1–3). Sixty patients (13%) died during a median follow-up period of 2 years. High serum albumin was independently associated with a better outcome (OR = 1.12, 95% CI = 1.05–1.20, p = 0.001). After adjusting for age, sex and NIHSS score on admission, high serum albumin was associated with lower mortality (OR = 0.88, 95% CI = 0.83–0.93, p < 0.0001). Conclusions: The current study indicates that high serum albumin is associated with better outcome and lower mortality in ischemic stroke patients. High serum albumin may be neuroprotective in ischemic stroke in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Albumin in Ischemic Stroke Patients: The Higher the Better

Idicula

Waje‐Andreassen²,

Brøgger³

et al. 2009

Cerebrovasc Dis

View full text Add to dashboard Cite

show abstract

“…103,104 In addition, albumin was suggested to exert anti-inflammatory effects by binding the proinflammatory lysolipid lysophosphatidylcholine. 105 To date, however, convincing findings on the neuroprotective mode of action of albumin are lacking. The ALIAS pilot trial suggested a favorable outcome when thrombolysis was combined with albumin.…”

Section: Candidate Drugs For Acute and Chronic Stroke Treatment Albuminmentioning

confidence: 99%

Multifunctional Actions of Approved and Candidate Stroke Drugs

Minnerup

Schäbitz

2009

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we describe the mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs. These drugs exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties. In addition, candidate stroke drugs currently studied in clinical phase III trials are described. Among these, albumin, hematopoietic growth factors, and citicoline have been identified as promising agents with multiple mechanisms. These drugs offer hope that additional treatment options for the acute phase after a stroke will become available in the near future.

show abstract

“…Albumin is recognized as an important antioxidant in plasma which might play a beneficial role during the delayed phase of neuronal death 14 . Seventh, it is also speculated that albumin might exert neuroprotection by binding to lysophosphatidylcholine (lyso PC) 15 SA level on admission is more likely to have good short-term outcome in ischaemic stroke patients than lower SA level. On previous studies, high SA was found to be independently associated with better outcome (OR = 1.12, 95% CI = 1.05-1.2, p = 0.001) 2 and lower SA level was found to be an independent predictor of poor outcome (OR=0.43, 95% CI = 0.26-0.70) of ischaemic stroke 9 .…”

Section: Discussionmentioning

confidence: 99%

Association of Serum Albumin with Short-Term Outcome of Ischemic Stroke

Azam¹,

Khan²,

Hussain³

et al. 2019

J. Natl Inst. Neurosci Bangladesh

View full text Add to dashboard Cite

Background: Serum albumin is proved to be a neuroprotective substance in experimental studies in focal cerebral ischemia. Objective: The aim of this study was to find out any association of serum albumin with the short term outcome of ischemic stroke. Methodology: This observational study was conducted in the Department of Neurology and Department of Internal Medicine at Dhaka Medical College Hospital, Dhaka from January 2011 to December 2011. A total of fifty consecutive patient with first ever ischemic stroke were included. Short term outcome was measured on day 7 using the modified Rankin Scale (mRS) and poor outcome was defined as mRS score 4 to 6 or death. Serum albumin was measured within 24 hours of onset of stroke. Result: Serum albumin was found to be significantly associated with the short-term outcome of ischemic stroke [P-value of Chi square (df = 1) was 0.010]. On logistic regression analysis, SA level [p = 0.018, Odds Ratio (OR) =5.817; 95% confidence interval: 1.348 to 25.106] remained significantly and positively associated with the short-term outcome of ischemic stroke. Conclusion: Serum albumin is significantly associated with the short-term outcome of ischemic stroke and lower level predicts poor outcome and higher level predicts good outcome. Journal of National Institute of Neurosciences Bangladesh, 2019;5(2): 101-105

show abstract

Molecular Mechanisms Underlying Neuroprotective Effects of Albumin After Ischemic Stroke

Cited by 9 publications

References 10 publications

Serum Albumin in Ischemic Stroke Patients: The Higher the Better

Serum Albumin in Ischemic Stroke Patients: The Higher the Better

Multifunctional Actions of Approved and Candidate Stroke Drugs

Association of Serum Albumin with Short-Term Outcome of Ischemic Stroke

Contact Info

Product

Resources

About